Sardar MZ Uddin

Sardar MZ Uddin


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SUSardar MZ Uddin
Sardar MZ Uddin
DKDavid Komatsu
David Komatsu
TMThomas Motyka
Thomas Motyka
SPStephanie C. Petterson
Stephanie C. Petterson
Therapeutic ultrasound has been studied for over seven decades for different medical applications. The versatility of ultrasound applications are highly dependent on the frequency, intensity, duration, duty cycle, power, wavelength, and form. In this review article, we will focus on low-intensity continuous ultrasound (LICUS). LICUS has been well-studied for numerous clinical disorders, including tissue regeneration, pain management, neuromodulation, thrombosis, and cancer treatment. PubMed and Google Scholar databases were used to conduct a comprehensive review of all research studying the application of LICUS in pre-clinical and clinical studies. The review includes articles that specify intensity and duty cycle (continuous). Any studies that did not identify these parameters or used high-intensity and pulsed ultrasound were not included in the review. The literature review shows the vast implication of LICUS in many medical fields at the pre-clinical and clinical levels. Its applications depend on variables such as frequency, intensity, duration, and type of medical disorder. Overall, these studies show that LICUS has significant promise, but conflicting data remain regarding the parameters used, and further studies are required to fully realize the potential benefits of LICUS.

1 April 2020 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
SUSardar MZ Uddin
Sardar MZ Uddin
DKDavid E. Komatsu
David E. Komatsu

15 December 2019 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
BHBernadette C Holdener
Bernadette C Holdener
CPChristopher J Percival
Christopher J Percival
RGRichard C Grady
Richard C Grady
DCDaniel C Cameron
Daniel C Cameron
SBSteven J Berardinelli
Steven J Berardinelli
RHRobert S Haltiwanger
Robert S Haltiwanger
Peters plus syndrome (MIM #261540 PTRPLS), characterized by defects in eye development, prominent forehead, hypertelorism, short stature and brachydactyly, is caused by mutations in the β3-glucosyltransferase (B3GLCT) gene. Protein O-fucosyltransferase 2 (POFUT2) and B3GLCT work sequentially to add an O-linked glucose β1-3fucose disaccharide to properly folded thrombospondin type 1 repeats (TSRs). Forty-nine proteins are predicted to be modified by POFUT2, and nearly half are members of the ADAMTS superfamily. Previous studies suggested that O-linked fucose is essential for folding and secretion of POFUT2-modified proteins and that B3GLCT-mediated extension to the disaccharide is essential for only a subset of targets. To test this hypothesis and gain insight into the origin of PTRPLS developmental defects, we developed and characterized two mouse B3glct knockout alleles. Using these models, we tested the role of B3GLCT in enabling function of ADAMTS9 and ADAMTS20, two highly conserved targets whose functions are well characterized in mouse development. The mouse B3glct mutants developed craniofacial and skeletal abnormalities comparable to PTRPLS. In addition, we observed highly penetrant hydrocephalus, white spotting and soft tissue syndactyly. We provide strong genetic and biochemical evidence that hydrocephalus and white spotting in B3glct mutants resulted from loss of ADAMTS20, eye abnormalities from partial reduction of ADAMTS9 and cleft palate from loss of ADAMTS20 and partially reduced ADAMTS9 function. Combined, these results provide compelling evidence that ADAMTS9 and ADAMTS20 were differentially sensitive to B3GLCT inactivation and suggest that the developmental defects in PTRPLS result from disruption of a subset of highly sensitive POFUT2/B3GLCT targets such as ADAMTS20.

12 October 2019 in Materials
Verified
Journal Article
Open access
PDF file
CHChaudhry Hassan
Chaudhry Hassan
YQYi-Xian Qin
Yi-Xian Qin
DKDavid Komatsu
David Komatsu
SUSardar MZ Uddin
Sardar MZ Uddin
Scaffold design plays an essential role in tissue engineering of articular cartilage by providing the appropriate mechanical and biological environment for chondrocytes to proliferate and function. Optimization of scaffold design to generate tissue-engineered cartilage has traditionally been conducted using in-vitro and in-vivo models. Recent advances in computational analysis allow us to significantly decrease the time and cost of scaffold optimization using finite element analysis (FEA). FEA is an in-silico analysis technique that allows for scaffold design optimization by predicting mechanical responses of cells and scaffolds under applied loads. Finite element analyses can potentially mimic the morphology of cartilage using mesh elements (tetrahedral, hexahedral), material properties (elastic, hyperelastic, poroelastic, composite), physiological loads by applying loading conditions (static, dynamic), and constitutive stress–strain equations (linear, porous–elastic, biphasic). Furthermore, FEA can be applied to the study of the effects of dynamic loading, material properties cell differentiation, cell activity, scaffold structure optimization, and interstitial fluid flow, in isolated or combined multi-scale models. This review covers recent studies and trends in the use of FEA for cartilage tissue engineering and scaffold design.

1 September 2020 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
BHBernadette C Holdener
Bernadette C Holdener
CPChristopher J Percival
Christopher J Percival
RGRichard C Grady
Richard C Grady
DCDaniel C Cameron
Daniel C Cameron
SBSteven J Berardinelli
Steven J Berardinelli
RHRobert S Haltiwanger
Robert S Haltiwanger
The authors wish to apologize for errors in B3glct Tm1Nari allele nomenclature in the above article. To be consistent with MGI (J:286130) nomenclature, this corrigendum has corrected nomenclature for B3glcttm1Nari alleles (MGI:727077, MGI:6277078, and MGI:6277079).